Letter to the editor concerning 'Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies'
- Resource Type
- Authors
- Jan Frystyk; Wajd Abbas Hassan; Rikke Hjortebjerg; Nils E. Magnusson; Nilani Ramshanker; Mette Bjerre
- Source
- Hassan, W A, Bjerre, M, Hjortebjerg, R, Magnusson, N E, Ramshanker, N & Frystyk, J 2014, ' Letter to the editor concerning "Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies" ', Annals of Oncology, vol. 26, no. 1, pp. 252 . https://doi.org/10.1093/annonc/mdu491
Hassan, W A, Bjerre, M, Hjortebjerg, R, Magnusson, N E, Ramshanker, N & Frystyk, J 2015, ' Letter to the editor concerning "Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies" ', Annals of Oncology, vol. 26, no. 1, pp. 252-253 . https://doi.org/10.1093/annonc/mdu491
- Subject
- Oncology
Male
medicine.medical_specialty
Letter to the editor
Colorectal cancer
medicine.medical_treatment
Astrocytoma
Insulin-like growth factor-binding protein
Elevated serum
Central Nervous System Neoplasms
Glioma
Internal medicine
medicine
Humans
Stage (cooking)
Autoantibodies
biology
business.industry
Growth factor
Carcinoma
Hematology
medicine.disease
Insulin-Like Growth Factor Binding Protein 2
biology.protein
Female
Antibody
business
Colorectal Neoplasms
- Language
- English
The objective of this letter is to make the readers aware of the difficulties we experienced when trying to reproduce the results by Li et al. “Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies”. The manuscript concluded that measurement of serum levels of auto-antibodies directed against insulin-like growth factor binding protein-2 (IGFBP-2) could potentially be used as diagnostic biomarkers in early cancer detection in patients suffering from glioma or colorectal cancer. Despite the exciting findings and the potential of using circulating IGFBP-2 auto-antibodies as early cancer biomarkers, we question the specificity of the in-house ELISA developed for IGFBP-2 auto-antibody measurement.